CITI/CALL/GILEAD SCIENCES/90/0.1/16.01.25 | Market Closed - Deutsche Boerse AG 01:37:51 2024-05-23 pm EDT | ||
| 0.001 EUR | -83.33% |
|
| Current month | +20.00% | ||
| 1 month | -86.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 0.001 | -83.33% |
| 24-05-22 | 0.006 | +20.00% |
| 24-05-21 | 0.005 | -68.75% |
| 24-05-20 | 0.016 | +6.67% |
| 24-05-17 | 0.015 | -11.76% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 01:37 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Citi
|
| WKN | KH2AKY |
| ISIN | DE000KH2AKY3 |
| Date issued | 2023-01-17 |
| Strike | 90 $ |
| Maturity | 2025-01-16 (238 Days) |
| Parity | 10 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.12 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.17
USD
Average target price
82.77
USD
Spread / Average Target
+25.09%
- Stock Market
- Warrants
- Warrant
